Ariella Bar-Gil Shitrit1, Yael Cohen2, Ori Hassin3, Ami Ben Ya'acov4, Rivkah Farkash2, Benjamin Koslowsky4, Yael Milgrom4, Dan Meir Livovsky4, Arnon Samueloff2, Eran Goldin4, Sorina Grisaru-Granovsky2. 1. IBD MOM Unit, Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Medical School, Hebrew University, Jerusalem, Israel. ariellash@szmc.org.il. 2. Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Affiliated with the Medical School, Hebrew University, Jerusalem, Israel. 3. Medical School, Ben Gurion University of the Negev, Beer Sheva, Israel. 4. IBD MOM Unit, Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Medical School, Hebrew University, Jerusalem, Israel.
Abstract
BACKGROUND: Inflammatory bowel disease affects women during their reproductive years and thus pregnancy outcomes. IBD MOM is a multidisciplinary, single-center clinic established to benefit women with IBD and their neonates. AIM: The aim of this study was to evaluate the perinatal outcomes of the IBD MOM clinic patients compared to patients who attended antenatal and gastrointestinal disease community clinics (IBD CC). METHODS: This single-center, prospective study was conducted from 2011 to 2015. The primary outcome was cesarean delivery; secondary was adverse perinatal outcomes. In parallel, a new pregnancy-oriented, disease severity score was evaluated for its association with perinatal risk (score low = 0 to severe = 5). RESULTS: We identified 90 women in the IBD MOM clinic and 206 in the IBD CC. Maternal age, smoking habits, pregnancy complications, and type of IBD (CD/UC) were similar between groups. Rates of labor induction and birth weight were also similar between IBD MOM and IBD GI. The IBD MOM overall preterm delivery (PTD) rate (< 37 weeks) was significantly higher 18.9 versus 9.7% (P = 0.028). The IBD MOM group had a significantly higher IBD MOM disease severity score that correlated with a higher rate of PTD. The overall IBD MOM score and scores > 3 were significantly associated with PTD risk in both groups (P = 0.013 and P = 0.004, respectively). CONCLUSION: Women with moderate and severe IBD who attended a multidisciplinary clinic may benefit from this unique center. Healthcare planning policies can assume that costly, multidisciplinary clinics for women with IBD should be reserved for those with moderate and severe disease.
BACKGROUND:Inflammatory bowel disease affects women during their reproductive years and thus pregnancy outcomes. IBD MOM is a multidisciplinary, single-center clinic established to benefit women with IBD and their neonates. AIM: The aim of this study was to evaluate the perinatal outcomes of the IBD MOM clinic patients compared to patients who attended antenatal and gastrointestinal disease community clinics (IBD CC). METHODS: This single-center, prospective study was conducted from 2011 to 2015. The primary outcome was cesarean delivery; secondary was adverse perinatal outcomes. In parallel, a new pregnancy-oriented, disease severity score was evaluated for its association with perinatal risk (score low = 0 to severe = 5). RESULTS: We identified 90 women in the IBD MOM clinic and 206 in the IBD CC. Maternal age, smoking habits, pregnancy complications, and type of IBD (CD/UC) were similar between groups. Rates of labor induction and birth weight were also similar between IBD MOM and IBD GI. The IBD MOM overall preterm delivery (PTD) rate (< 37 weeks) was significantly higher 18.9 versus 9.7% (P = 0.028). The IBD MOM group had a significantly higher IBD MOM disease severity score that correlated with a higher rate of PTD. The overall IBD MOM score and scores > 3 were significantly associated with PTD risk in both groups (P = 0.013 and P = 0.004, respectively). CONCLUSION:Women with moderate and severe IBD who attended a multidisciplinary clinic may benefit from this unique center. Healthcare planning policies can assume that costly, multidisciplinary clinics for women with IBD should be reserved for those with moderate and severe disease.
Authors: C Sack; V A Phan; R Grafton; G Holtmann; D R van Langenberg; K Brett; M Clark; J M Andrews Journal: J Crohns Colitis Date: 2011-10-12 Impact factor: 9.071
Authors: A Bortoli; N Pedersen; D Duricova; R D'Inca; P Gionchetti; M R Panelli; S Ardizzone; A L Sanroman; J P Gisbert; I Arena; G Riegler; M Marrollo; D Valpiani; A Corbellini; S Segato; F Castiglione; P Munkholm Journal: Aliment Pharmacol Ther Date: 2011-08-04 Impact factor: 8.171
Authors: Alison de Lima; Zuzana Zelinkova; Annemarie G M G J Mulders; C Janneke van der Woude Journal: Clin Gastroenterol Hepatol Date: 2016-03-18 Impact factor: 11.382
Authors: Alyshah Abdul Sultan; Joe West; Lu Ban; David Humes; Laila J Tata; Kate M Fleming; Catherine Nelson-Piercy; Timothy Card Journal: Inflamm Bowel Dis Date: 2016-07 Impact factor: 5.325